Pharmacological correction of pathological changes in the viable offspring of rats, caused by cytostatic impact at the stage of progenesis

Background. The number of reproductive-aged women with cancer, who desire child bearing, has increased with improvements in cancer detection and treatment. Cancer treatments have the potential to cause germline mutations that might increase the risk of cancer in the progeny of cancer patients. the aim of the study was to assess the feasibility of reducing the long-term side effects of Etoposide on the progeny of rats using Glutaxim. material and methods. Forty-five white outbred female Wistar rats, 2.5-month-old, were divided into 3 groups. Group I consisted of 15 intact rats. Group II comprised 15 rats treated with cytostatic drug (the control group). Group III consisted of 15 rats treated with Glutoxim® (Glutayil-Cysteinyl-Glycine, Pharma Vam Ltd., Russia) at a dose of 50 μg/kg 5 days before and 5 days after receiving cytostatic drug. results. An increase in the number of fetuses with external hemorrhages and pathological changes in internal organs was found in the progeny of female rats receiving Etoposide 3 months before mating. The progeny experienced a decrease in the rate of formation of sensory-motor reflexes, ability to learn and adaptive behavior. All studied parameters did not differ from background values in the progeny of female rats treated with combination of Etoposide and Glutoxim. conclusion. Glutaxim is the effective drug for correction of pathological changes in the progeny of female rats receiving cytostatic drugs.